Discuss how the One Health approach under NAP-AMR 2.0 can address the multi-sectoral drivers of AMR in India.
New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →Antimicrobial resistance (AMR) does not stay in one sector. Resistant microbes and drug residues move between people, animals, farms and the environment. India released NAP-AMR 2.0 (2025–29) in November 2025. It is built on a One Health approach that links action across the human, animal, agriculture and environment sectors [1][2]. This joined-up approach suits a problem with joined-up causes.
Multi-sectoral drivers of AMR
- Human health: Antibiotics are used irrationally. Regulators are concerned that manufacturing licences for antimicrobials are granted without adequate scrutiny [5].
- Animal and plant health: Antimicrobials used in livestock and farming add to resistance. This is why the plan covers animal and plant health, not only human health [2].
- Environment: WHO says antibiotic pollution from manufacturing is largely unregulated. Standard quality checks ignore what factories release [4].
- Governance: Parliament has flagged lapses in CDSCO's drug-approval process, which weakens control at the source [6].
How One Health under NAP-AMR 2.0 helps
- Sector-wise accountability: Each sector acts in its own domain, and this is the base for intersectoral collaboration among ministries over five years [1].
- Shared evidence: One framework across human, animal and plant health lets data from one sector guide action in another [2].
- Learning from the past: It builds on the first NAP-AMR (2017–21), which recorded the state of AMR containment in India [3].
- Regulatory backing: The Health Ministry's draft rules add antimicrobials to the 'New Drug' definition under the NDCT Rules, 2019. They also create a separate bulk-drug sale licence under the Drugs Rules, 1945 [5].
- Environmental limits: WHO's 2024 guidance sets discharge targets for every stage, from making APIs to the finished product. It is written for regulators and buyers to adopt [4].
Gaps to close
- The bulk-drug licence tracks who trades APIs, not what plants release, so environmental controls need their own rules [5][4].
- Central scrutiny needs more CDSCO capacity, or approvals will just slow down [6].
The One Health approach under NAP-AMR 2.0 brings sectors that work separately into one shared effort against AMR. To deliver, India should put WHO discharge targets into licence conditions, strengthen CDSCO, and track each ministry's progress publicly. That would turn the plan's One Health promise into results and advance SDG 3 (good health) under WHO's Global Action Plan on AMR.
Sources
- 1PIB: Union Health Minister Shri J P Nadda Launches National Action Plan on Antimicrobial Resistance 2.0 (18 Nov 2025): launch, One Health, sectoral action as the base for intersectoral collaboration
- 2NCDC, MoHFW: National Action Plan on Antimicrobial Resistance (NAP-AMR) 2025–2029: 2025–29 timeframe, coverage of human, animal and plant health
- 3WHO India: National Action Plan on Antimicrobial Resistance (NAP-AMR) 2017–2021: first plan, a record of AMR containment status
- 4WHO: Guidance on wastewater and solid waste management for manufacturing of antibiotics (2024): manufacturing pollution largely unregulated, discharge targets from API to finished product, written for regulators and buyers
- 5The Hindu: "Ministry seeks tighter norms for antimicrobials, bulk trade" (20 Nov 2026, news report): draft NDCT Rules 'New Drug' amendment, separate bulk-drug sale licence, concern over licensing without adequate scrutiny
- 6PRS Legislative Research: Lapses in the process of drug approval in India: Parliamentary Standing Committee findings on CDSCO approval lapses